TriSalus Life Sciences (NASDAQ:TLSIW) Shares Up 13.9% – Here’s What Happened

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW)’s share price traded up 13.9% during mid-day trading on Friday . The company traded as high as $1.64 and last traded at $1.64. 1,587 shares changed hands during mid-day trading, a decline of 80% from the average session volume of 7,977 shares. The stock had previously closed at $1.44.

TriSalus Life Sciences Stock Performance

The stock’s 50-day moving average is $1.28 and its 200 day moving average is $1.52.

Institutional Trading of TriSalus Life Sciences

A hedge fund recently raised its stake in TriSalus Life Sciences stock. Citadel Advisors LLC increased its holdings in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) by 439.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 126,876 shares of the company’s stock after buying an additional 103,336 shares during the quarter. Citadel Advisors LLC’s holdings in TriSalus Life Sciences were worth $199,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage medical device company focused on developing minimally invasive technologies to enhance the precision and efficacy of cancer radiation therapy. The company’s lead product, the TriMark™ Tissue Marker System, is designed to provide high-visibility soft-tissue fiducial markers that assist oncologists in accurately targeting tumors during radiotherapy. By deploying bio-absorbable markers directly into tumor beds, TriSalus aims to improve treatment planning, patient comfort and long-term follow-up imaging.

Founded in 2015 and headquartered in Plymouth, Minnesota, TriSalus Life Sciences pursues a platform approach to oncology treatment, with research and development efforts centered on novel delivery devices and advanced imaging solutions.